ITP patients with platelet count below 150,000/L Helicobacter pylori screening ITP triple therapy
Conditions
Interventions
Helicobacter pylori screening with commercial immunochromatographic blood test and urea breath test
Triple therapy for Helicobacter pylori infection consists of omeprazole 20 mg oral twice daily, clar
Helicobacter pylori screening,Non Helicobacter pylori screening
Sponsors
Faculty of Medicine, Chiang Mai university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Acute, persistent and chronic Immune Thrombocytopenic Purpura with 18 years of age or older 2. Immune Thrombocytopenic Purpura disease, either primary and secondary from SLE 3. platelet at enrollment below 150,000/L
Exclusion criteria
Exclusion criteria: 1. Currently use or history of triple therapy use within 1 year before enrollment 2. Currently use or history of antibiotics or bismuth agent use within 1 month before enrollment 3. History of allergy or severe adverse event from amoxicillin, clarithromycin and omeprazole 4. HIV or HCV infection and active malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean difference of platelet count 3, 6 and 12 months blood | — |
Secondary
| Measure | Time frame |
|---|---|
| response of treatment between groups 3, 6 and 12 months blood,prevalence of Helicobacter pylori infection first enrollment blood and urea breath test,success rate of triple therapy 3 months stool Ag test,cumulative dose of prednisolone between groups 3, 6 and 12 months prednisolone doses,quality of life between groups 0, 6 and 12 months Questionnaire,efficacy of ICT test compared with first enrollment blood | — |
Countries
Thailand
Contacts
Public Contactkhanittha siritham
Maharaj nakorn Chaing Mai
Outcome results
None listed